Krystal Biotech ( (KRYS) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Krystal Biotech shares climbed after the company reported solid progress across its drug pipeline, including advances in its dystrophic epidermolysis bullosa program, a positive cystic fibrosis data readout, and RMAT designation for its KB707 therapy in NSCLC. Analysts responded by generally lifting their price targets, signaling growing confidence in the company’s long‑term outlook.
Looking further ahead, Krystal Biotech guided its fiscal 2026 non‑GAAP R&D and SG&A expenses to a range of $175 million to $195 million. Investors viewed the spending plan as manageable given the expanding clinical portfolio, reinforcing optimism around the stock’s upward move.
More about Krystal Biotech
YTD Price Performance: 12.13%
Average Trading Volume: 286,031
Technical Sentiment Signal: Buy
Current Market Cap: $8.02B
For further insights into KRYS stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.